αGalCer-RBD

Cat. No.: IBDI-434731

αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist. RBD: receptor-binding domain

Product Details

Target	SARS-CoV
Molecular Weight	1119.60
SMILES	O[[email protected]]1[[email protected]]([[email protected]](O[[email protected]@H]([[email protected]@H]1O)OC[[email protected]@H]([[email protected]@H]([[email protected]@H](CCCCCCCCCCCCCC)O)O)NC(C#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC)=O)CNC(COCCOCCOCCNC(CON)=O)=O)O.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.